Directorate Change

AstraZeneca PLC
25 July 2007

AstraZeneca PLC appoints new Non-Executive Director



AstraZeneca today announced that Bo Angelin is to join the Board of Directors as
a Non-Executive Director with immediate effect.  Bo Angelin is currently
Professor of Clinical Metabolism at Karolinska Institutet and Head of the
Department of Endocrinology, Metabolism and Diabetes at the Karolinska
University Hospital in Stockholm, Sweden, where his research group is studying
the regulation of lipid metabolism in the liver by genes, diets, and hormones in
order to find new ways of eliminating cholesterol from the body.



Louis Schweitzer, Chairman of AstraZeneca, said: 'I am delighted that Bo Angelin
has agreed to join us.  His considerable experience in medical research and the
practice of medicine will be of great benefit to the work of the Board'.



No disclosure obligations arise under paragraphs (1) to (6) of Listing Rule
9.6.13 of the UK Listing Authority's Listing Rules in respect of the appointment
of Bo Angelin.



25 July 2007

Media Enquiries:

Steve Brown (London) [phone]

Edel McCaffrey (London) [phone]



Analyst/Investor Enquiries:

Jonathan Hunt (London) [phone]

Mina Blair (London) [phone]

Karl Hard (London) [phone]

Ed Seage (US) [phone]

Jorgen Winroth (US) [phone]



-Ends-


                      This information is provided by RNS
            The company news service from the London Stock Exchange